Outcomes of primary gastrointestinal diffuse large B cell lymphoma in the rituximab era
Luyao Zhang, Jianwen Zhou, Yanyan Sun, Yaodong Zhang et al. • Discover Oncology
(2026)
Abstract Background Primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) constitutes 30%-40% of primary extranodal lymphomas. While rituximab has significantly improved survival in nodal DLBCL, its impact on the prognosis of P...
DOAJ
Open Access (DOAJ)
DOI:
10.1007/s12672-026-05022-z